Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Public ClinicalTrials.gov record NCT05206513. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Study identification
- NCT ID
- NCT05206513
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Not listed
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 6 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2022
- Primary completion
- Oct 15, 2025
- Completion
- Mar 30, 2026
- Last update posted
- Apr 28, 2026
2022 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Clinical Site | San Diego | California | 92123 | — |
| Neurocrine Clinical Site | Aurora | Colorado | 80045 | — |
| Neurocrine Clinical Site | Stamford | Connecticut | 06905 | — |
| Neurocrine Clinical Site | Gulf Breeze | Florida | 32561 | — |
| Neurocrine Clinical Site | Miami | Florida | 33155 | — |
| Neurocrine Clinical Site | Orlando | Florida | 32806 | — |
| Neurocrine Clinical Site | Chicago | Illinois | 60611 | — |
| Neurocrine Clinical Site | Baltimore | Maryland | 21205 | — |
| Neurocrine Clinical Site | Boston | Massachusetts | 02115 | — |
| Neurocrine Clinical Site | Farmington Hills | Michigan | 48334 | — |
| Neurocrine Clinical Site | Saint Paul | Minnesota | 55101 | — |
| Neurocrine Clinical Site | New York | New York | 10003 | — |
| Neurocrine Clinical Site | Cincinnati | Ohio | 45229 | — |
| Neurocrine Clinical Site | Columbus | Ohio | 43205 | — |
| Neurocrine Clinical Site | Oklahoma City | Oklahoma | 73120 | — |
| Neurocrine Clinical Site | Portland | Oregon | 97239 | — |
| Neurocrine Clinical Site | Dallas | Texas | 75390-8857 | — |
| Neurocrine Clinical Site | Fort Worth | Texas | 76104 | — |
| Neurocrine Clinical Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05206513, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05206513 live on ClinicalTrials.gov.